In the early 2020, the world has been shook by the pandemic of coronavirus reported in Wuhan, China in December 2019. This pandemic source was identified as class of coronavirus (CoV) and first reported in late 2019, thus named as COVID-19. COVID-19 virus belongs to the family of virus including Ebola virus, SARS, and MERS. It causes a respiratory malady showing symptoms of pneumonia. Globally, the countries have been fighting the virus; however, till date no effective treatment has been identified. Currently, the major concern is the contagious nature of virus. Many antivirals have been tested, and clinical trials are done which produced a data of many antiviral drugs which to an extent have been found effective for combating the pandemic like favipiravir, remdesivir, ribavirin, ritonavir, lopinavir but not a single one has proven to be 100% effective in treatment, only attenuation of the symptoms of COVID-19 are noted. Favipiravir has shown promising results based on its clinical trials and became the first candidate in China to help the people fight this infection. Favipiravir exhibited significantly positive results on the patients and opened up a prominent place in the class of antivirals and has already proven itself in the treatment of influenza virus and other viral diseases including MERS, arenavirus, and filovirus. Therefore, favipiravir has come out as a promising antiviral and can be thought of a suitable candidate in case of any antiviral disease including COVID-19 and has shown prominent results within a time frame of 1 to 2 weeks. In this review, we have summarized the introduction, mode of action, clinical status of favipiravir, and its future perspectives in the infection treatment.